Basal‑Bolus Insulin Is the Preferred Regimen for Hospitalized Adults with Diabetes

1. Guideline Position on Sliding‑Scale Insulin (SSI)

• The American Diabetes Association (ADA) strongly recommends against using SSI as monotherapy for hospitalized adults with diabetes, stating it should be discontinued immediately in favor of scheduled basal‑bolus therapy. Strong recommendation (Grade A). [1][2]

2. Clinical Effectiveness of Basal‑Bolus vs. SSI

• In non‑critically ill hospitalized patients, ≈68 % achieve a mean glucose < 140 mg/dL with a scheduled basal‑bolus regimen, compared with ≈38 % on SSI alone. Strong recommendation (Grade A). 1
• Basal‑bolus therapy does not increase hypoglycemia incidence relative to SSI, while providing superior overall glycemic control. Strong recommendation (Grade A). 1

3. Initial Dosing of Basal‑Bolus Insulin

3.1 Standard‑Risk Patients (insulin‑naïve or low‑dose home therapy)

• Start total daily dose (TDD) 0.3–0.5 U/kg/day, split 50 % basal (once daily) and 50 % prandial (divided among three meals). Strong recommendation (Grade A). [1][2]

3.2 High‑Risk Patients (age > 65 yr, renal impairment, poor oral intake)

• Use a reduced TDD 0.1–0.25 U/kg/day to limit hypoglycemia risk. Strong recommendation (Grade A). [1][2]

3.3 Patients on High‑Dose Home Insulin (≥0.6 U/kg/day)

• Reduce the admission TDD by ≈20 % relative to home dose. Strong recommendation (Grade A). 1

4. Basal Insulin Titration

• Increase basal dose by 2 U every 3 days if fasting glucose is 140–179 mg/dL. Strong recommendation (Grade A). [1][2]
• Increase basal dose by 4 U every 3 days if fasting glucose is ≥180 mg/dL. Strong recommendation (Grade A). [1][2]
• Target fasting glucose 80–130 mg/dL. Strong recommendation (Grade A). [1][2]
• When basal dose reaches 0.5–1.0 U/kg/day without achieving target fasting glucose, add prandial insulin rather than further escalating basal. Strong recommendation (Grade A). [1][2]

5. Prandial Insulin Initiation and Titration

5.1 Starting Dose

• Administer 4 U rapid‑acting insulin before each of the three largest meals (≈10 % of current basal dose). Strong recommendation (Grade A). [1][2]

5.2 Timing

• Give prandial insulin 0–15 minutes before meals. Strong recommendation (Grade A). [1][2]

5.3 Titration

• Adjust each meal dose by 1–2 U (≈10–15 %) every 3 days based on the 2‑hour post‑prandial glucose. Strong recommendation (Grade A). [1][2]
• Target post‑prandial glucose < 180 mg/dL. Strong recommendation (Grade A). [1][2]

6. Correction (Adjunct) Doses

• Add 2 U rapid‑acting insulin for pre‑meal glucose > 250 mg/dL. Strong recommendation (Grade A). [1][2]
• Add 4 U for pre‑meal glucose > 350 mg/dL. Strong recommendation (Grade A). [1][2]
• Correction doses must supplement, not replace, scheduled basal and prandial insulin. Strong recommendation (Grade A). [1][2]

7. Glucose Monitoring Protocol

7.1 Patients Eating Regular Meals

• Check glucose before each meal and at bedtime (minimum four times daily). Strong recommendation (Grade A). [1][2]

7.2 Patients with Poor Intake or NPO

• Check glucose every 4–6 hours. Strong recommendation (Grade A). [1][2]

7.3 Guiding Adjustments

• Use daily fasting glucose to guide basal insulin titration. Strong recommendation (Grade A). [1][2]
• Obtain 2‑hour post‑prandial glucose after each meal to assess prandial adequacy. Strong recommendation (Grade A). [1][2]

8. Hypoglycemia Management

• Treat glucose < 70 mg/dL promptly with 15 g fast‑acting carbohydrate, recheck in 15 minutes, and repeat if needed. Strong recommendation (Grade A). [1][2]
• If hypoglycemia occurs without an obvious cause, reduce the implicated insulin dose by 10–20 % immediately. Strong recommendation (Grade A). [1][2]

9. Implementation Algorithm (Key Steps)

Insulin Therapy Recommendations for Hospitalized Patients

Introduction to Insulin Regimens

• The American Diabetes Association recommends a basal-bolus insulin regimen over sliding scale insulin alone for hospitalized patients due to superior glycemic control and reduced complications 3, 4
• Sliding scale insulin alone is associated with clinically significant hyperglycemia and should not be used as the initial approach for patients with type 1 diabetes 3

Limitations of Sliding Scale Insulin

• Sliding scale insulin treats hyperglycemia reactively, leading to rapid blood glucose fluctuations that exacerbate both hyper- and hypoglycemia 5, 6
• Sliding scale insulin regimens are often used throughout hospital stays without modification, even when control remains poor 5, 6

Recommended Initial Approach

• For insulin-naive patients or those on low insulin doses, start with a total daily insulin dose of 0.3-0.5 units/kg, with half allocated to basal insulin and half to rapid-acting insulin 3
• Lower doses should be used for patients at higher risk of hypoglycemia, such as older patients or those with renal failure 3
• For patients already on higher insulin doses, reduce the total daily insulin dose by 20% during hospitalization to prevent hypoglycemia 3

Evidence Supporting Recommendations

• Randomized trials consistently show better glycemic control with basal-bolus approaches compared to sliding scale insulin alone in patients with type 2 diabetes 3
• The basal-bolus approach is associated with reduced complications, including postoperative wound infection and acute renal failure 3
• Glycemic control, defined as mean blood glucose <140 mg/dl, was achieved in 68% of patients receiving basal-bolus insulin versus only 38% of those receiving sliding scale insulin alone 5, 6

Special Considerations

• For patients with mild stress hyperglycemia without diabetes, sliding scale insulin might be appropriate 3
• For patients transitioning from IV insulin infusion to subcutaneous insulin, calculate the daily dose based on the average insulin infused during the previous 12 hours 4
• When using a simplified sliding scale, consider giving 2 units of short- or rapid-acting insulin for premeal glucose >250 mg/dL and 4 units for premeal glucose >350 mg/dL 7, 8

Monitoring and Adjustment

• If correction doses are frequently required, increase the scheduled insulin doses accordingly 5, 6
• Target a conventional glucose range of 140-180 mg/dL for most hospitalized patients 3

Cautions and Pitfalls

• Basal-bolus approach may lead to hypoglycemia in 12-30% of patients in controlled settings 3
• Avoid premixed insulin therapy in the hospital as it has been associated with unacceptably high rates of hypoglycemia 4

Insulin Management in Hospitalized Patients

Introduction to Insulin Regimens

• The American Diabetes Association recommends scheduled insulin regimens with basal insulin as the foundation, using correction doses of rapid-acting insulin for hyperglycemia rather than sliding scale insulin (SSI) alone 9, 10

Preferred Insulin Regimens

• For patients with good oral intake, the Endocrine Society suggests starting with a basal-bolus regimen: 0.3-0.5 units/kg total daily dose, divided 50% basal (once daily) and 50% prandial (before meals) 10
• For patients with poor oral intake or NPO, Diabetes Canada recommends a basal-plus approach: 0.1-0.25 units/kg/day of basal insulin plus correction doses of rapid-acting insulin for hyperglycemia 10

Acceptable Use of Sliding Scale Insulin

• The American Diabetes Association suggests that SSI might be acceptable for patients with mild stress hyperglycemia without pre-existing diabetes, patients with well-controlled diabetes (HbA1c <7%) on minimal home therapy who have mild hyperglycemia during hospitalization, patients who are NPO with no nutritional replacement and only mild hyperglycemia, and patients who are new to steroids or tapering steroids 9

Insulin Dosing Considerations

• The Australian Diabetes Society recommends reducing total daily dose by 20% during hospitalization for patients on high insulin doses at home (≥0.6 units/kg/day) to prevent hypoglycemia 10
• The Endocrine Society advises against using premixed insulin (70/30) in hospitals due to unacceptably high hypoglycemia rates 10

Hospitalized Adult Insulin Management (American Diabetes Association Guidelines)

General Recommendations

• The American Diabetes Association strongly recommends discontinuing sliding‑scale insulin (SSI) monotherapy for hospitalized patients with established insulin needs and replacing it with a scheduled basal‑bolus regimen. Strong recommendation 11
• SSI should be used only in very limited situations (mild stress hyperglycemia without prior diabetes, well‑controlled type 2 diabetes on diet/oral agents with mild hyperglycemia, NPO with mild hyperglycemia, or new/tapering steroid therapy). Conditional recommendation 11

Efficacy of Basal‑Bolus vs Sliding‑Scale

• Approximately 68 % of patients achieve a mean glucose < 140 mg/dL with a basal‑bolus regimen, compared with ≈38 % when SSI is used alone; the basal‑bolus approach does not increase overall hypoglycemia when properly implemented. Level A evidence [12][11]

Initial Dosing Strategies

• Rapid‑acting insulin should be administered 0–15 minutes before meals (ideally immediately before eating) for optimal post‑prandial control. Recommendation 11
• Rapid‑acting insulin must never be given at bedtime as a sole correction dose because it markedly raises nocturnal hypoglycemia risk. Recommendation 11

Titration Protocols

Basal Insulin

• Increase basal dose by 2 U every 3 days if fasting glucose is 140–179 mg/dL. Recommendation 11
• Increase basal dose by 4 U every 3 days if fasting glucose is ≥180 mg/dL. Recommendation 11
• Target fasting glucose 80–130 mg/dL. Recommendation 11
• When basal insulin reaches 0.5–1.0 U/kg/day without achieving targets, add or intensify prandial insulin rather than further increase basal dose. Recommendation 11

Prandial (Humalog) Insulin

• Start with 4 U before each of the three largest meals (or ≈10 % of the current basal dose). Recommendation 11
• Increase each meal dose by 1–2 U (≈10–15 %) every 3 days based on the 2‑hour post‑prandial glucose reading. Recommendation 11
• Target post‑prandial glucose < 180 mg/dL. Recommendation 11

Glucose Monitoring

• Patients eating regular meals: check glucose before each meal and at bedtime (minimum 4 times daily). Recommendation 11
• Patients with poor oral intake or NPO: check glucose every 4–6 hours. Recommendation 11
• For NPO patients, use a basal‑plus‑correction regimen (basal insulin plus correction doses only) rather than scheduled prandial insulin. Recommendation 11
• Use daily fasting glucose to guide basal insulin titration and obtain a 2‑hour post‑prandial glucose after each meal to assess prandial adequacy. Recommendation 11

Hypoglycemia Management

• Treat glucose < 70 mg/dL promptly with ≈15 g of fast‑acting carbohydrate, recheck in 15 minutes, and repeat if needed. Recommendation 11
• If hypoglycemia occurs without an obvious cause, reduce the implicated insulin dose by 10–20 % immediately. Recommendation 11
• Document every hypoglycemic episode in the medical record for quality‑tracking purposes. Recommendation 11

Safety Pitfalls (What to Avoid)

• Do not use SSI as monotherapy in patients with type 1 diabetes or established insulin requirements (risk of diabetic ketoacidosis). Recommendation 12
• Do not continue SSI unchanged throughout hospitalization when glucose control remains poor. Recommendation 12
• Do not delay transition to a scheduled basal‑bolus regimen when glucose values repeatedly exceed 180 mg/dL. Recommendation 12
• Do not rely solely on correction doses without adjusting scheduled basal and prandial insulin when frequent corrections are needed. Recommendation 12
• Do not give rapid‑acting insulin at bedtime as a sole correction dose (increases nocturnal hypoglycemia risk). Recommendation 11

Expected Clinical Outcomes

• With properly implemented basal‑bolus therapy using rapid‑acting analogs, ≈68 % of patients achieve mean glucose < 140 mg/dL versus ≈38 % with SSI alone. Level A evidence [12][11]
• Basal‑bolus regimens do not increase overall hypoglycemia incidence compared with inadequate SSI approaches. Level A evidence [12][11]
• The recommended target glucose range for non‑critically ill hospitalized patients is 140–180 mg/dL. Recommendation 11

Distinguishing Corrective Insulin from Sliding‑Scale Insulin and Implementing Evidence‑Based Regimens

1. Definition and Appropriate Use

• Corrective insulin is a supplemental rapid‑acting dose added to a scheduled basal‑bolus regimen when pre‑meal glucose exceeds a predefined threshold; it is never used as a replacement for basal or prandial insulin. 13
• Sliding‑scale insulin (SSI) consists solely of reactive rapid‑acting doses administered after a high glucose reading, with no scheduled basal or prandial insulin, and is therefore considered a monotherapy regimen. 13

2. Guideline Stance

• The American Diabetes Association (ADA) and all major diabetes guideline societies explicitly condemn SSI as monotherapy and recommend its immediate discontinuation in favor of a scheduled basal‑bolus approach. 13

3. Clinical Effectiveness

• In hospitalized patients, ≈38 % achieve a mean glucose < 140 mg/dL with SSI alone, versus ≈68 % when a scheduled basal‑bolus regimen (including corrective insulin) is used. 13
• Treatment failure (≥ 2 consecutive glucose readings > 240 mg/dL) occurs in ≈19 % of patients on SSI compared with 0–2 % on basal‑bolus therapy. 13

4. Recommended Regimen Structure

• Three‑component insulin regimen for all insulin‑requiring patients:
  
  • Basal insulin (e.g., glargine, detemir, degludec) once daily for continuous background coverage.
  • Prandial insulin (rapid‑acting analogs) administered 0–15 min before each meal to cover meal‑related glucose excursions.
  • Correction insulin given only as a supplement when pre‑meal glucose exceeds target thresholds. 13

5. Initial Dosing for Hospitalized Adults

Both dosing strategies are recommended for hospitalized adults initiating insulin therapy. 13

6. Titration Protocols

• Basal insulin: increase by 2 U every 3 days if fasting glucose 140–179 mg/dL; increase by 4 U every 3 days if fasting ≥ 180 mg/dL, targeting 80–130 mg/dL. 13
• Prandial insulin: increase each meal dose by 1–2 U (≈10–15 %) every 3 days based on 2‑hour post‑prandial glucose, targeting < 180 mg/dL. 13
• Correction doses: use a simplified scale (2 U for glucose > 250 mg/dL, 4 U for glucose > 350 mg/dL) in addition to scheduled basal and prandial doses, or calculate using the insulin sensitivity factor (ISF = 1500 ÷ total daily insulin dose). 13

7. Safety Considerations

• Treat glucose < 70 mg/dL promptly with 15 g of fast‑acting carbohydrate; re‑check in 15 minutes and repeat if needed. Reduce the implicated insulin dose by 10–20 % before the next administration if hypoglycemia occurs without an obvious cause. 13
• Never use rapid‑acting insulin at bedtime as a sole correction dose, as this markedly raises the risk of nocturnal hypoglycemia. 13
• Do not rely exclusively on correction doses without adjusting scheduled basal and prandial insulin when frequent corrections are required. 13

8. Expected Outcomes with Evidence‑Based Regimen

• Properly implemented basal‑bolus therapy (including corrective insulin) achieves mean glucose < 140 mg/dL in ≈68 % of patients, compared with ≈38 % using SSI alone. 13
• When titrated appropriately, basal‑bolus therapy does not increase overall hypoglycemia incidence relative to inadequate SSI approaches. 13